Real-World Effectiveness and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Adult Patients: A 52-Week Multicenter Retrospective Study
Restricted accessLetterFirst published online March, 2025
Real-World Effectiveness and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Adult Patients: A 52-Week Multicenter Retrospective Study
MarkhamA. Tildrakizumab: first global approval. Drugs. 2018;78(8):845-849. doi:10.1007/s40265-018-0917-3
2.
ReichKPappKABlauveltA, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials [published correction appears in Lancet. 2017 Jul 15;390(10091):230. doi: 10.1016/S0140-6736(17)31834-2]. Lancet. 2017;390(10091):276-288. doi:10.1016/S0140-6736(17)31279-5
3.
KimballABPappKAReichK, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2020;182(6):1359-1368. doi:10.1111/bjd.18484
4.
ReichKWarrenRBIversenL, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks [published correction appears in Br J Dermatol. 2022 Jul;187(1):131-132. doi: 10.1111/bjd.20960]. Br J Dermatol. 2020;182(3):605-617. doi:10.1111/bjd.18232
5.
HeimJVasquezJGBhutaniT, et al. Tildrakizumab real-world effectiveness and safety over 64 weeks in patients with moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2024;23(8):612-618. doi:10.36849/JDD.8217
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
